Home › Funds › Remedium Capital Partners, LLC › APGE
Remedium Capital Partners, LLC position in APGE
APOGEE THERAPEUTICS INC
Remedium Capital Partners, LLC reported holding 586,691 shares of APGE (APOGEE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$77.9M, representing 17.24% of its reported portfolio and ranking #3 among its reported holdings. Remedium Capital Partners, LLC has disclosed APGE holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Remedium Capital Partners, LLC's APGE position evolved
Remedium Capital Partners, LLC first disclosed a stake in APGE in Q4 2025 at 583,591 shares (US$44.0M). The position peaked in Q2 2026 at 586,691 shares, worth US$77.9M. Across 3 filings, Remedium Capital Partners, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 586,691 shares valued at US$77.9M — an increase of 3,100 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 583.59K | $44.05M | New |
| Q1 2026 | 583.59K | $49.12M | Hold |
| Q2 2026 | 586.69K | $77.87M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About APGE and 13F data
APGE (APOGEE THERAPEUTICS INC) is a company whose sector is not yet classified in our data. 59 other funds we track also report a position in APGE — the largest reported positions include Venrock Adviser, LLC (US$1.13B), HBK INVESTMENTS L P (US$378.3M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$231.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding APGE
- Venrock Adviser, LLC 8.49M sh · $1.13B · Q2 2026
- HBK INVESTMENTS L P 2.85M sh · $378.28M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 1.74M sh · $230.96M · Q2 2026
- GLAZER CAPITAL, LLC 1.64M sh · $217.82M · Q2 2026
- Paradigm Biocapital Advisors LP 1.58M sh · $209.23M · Q2 2026
- Pentwater Capital Management LP 1.43M sh · $189.14M · Q2 2026
- PERCEPTIVE ADVISORS LLC 1.31M sh · $173.63M · Q2 2026
- Affinity Asset Advisors, LLC 987.00K sh · $131.00M · Q2 2026
- First Light Asset Management, LLC 930.29K sh · $123.48M · Q2 2026
- Kryger Capital LLC 742.55K sh · $98.56M · Q2 2026
- First Trust Capital Management L.P. 625.18K sh · $82.98M · Q2 2026
- Soros Fund Management 564.50K sh · $74.93M · Q2 2026
More on Remedium Capital Partners, LLC
FAQ
How long has Remedium Capital Partners, LLC held APGE?
Remedium Capital Partners, LLC has disclosed APGE holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Remedium Capital Partners, LLC's current position in APGE?
As of Q2 2026, Remedium Capital Partners, LLC holds 586.69K shares of APGE (APOGEE THERAPEUTICS INC), valued at $77.87M, representing 17.24% of its reported portfolio and ranking #3.
Has Remedium Capital Partners, LLC been buying or selling APGE?
In the latest 13F filing (Q2 2026), Remedium Capital Partners, LLC increased its position in APGE. The position peaked in Q2 2026 at 586.69K shares.
Which other funds hold APGE?
Other major institutional holders of APGE include Venrock Adviser, LLC, HBK INVESTMENTS L P, DRIEHAUS CAPITAL MANAGEMENT LLC, among 59 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.